Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gross Profit (2016 - 2025)

Historic Gross Profit for NovaBay Pharmaceuticals (NBY) over the last 13 years, with Q3 2025 value amounting to $42000.0.

  • NovaBay Pharmaceuticals' Gross Profit changed N/A to $42000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 8158.42%. This contributed to the annual value of $6.5 million for FY2024, which is 652.53% up from last year.
  • NovaBay Pharmaceuticals' Gross Profit amounted to $42000.0 in Q3 2025.
  • NovaBay Pharmaceuticals' Gross Profit's 5-year high stood at $6.5 million during Q4 2024, with a 5-year trough of $42000.0 in Q3 2025.
  • For the 5-year period, NovaBay Pharmaceuticals' Gross Profit averaged around $1.9 million, with its median value being $1.7 million (2021).
  • In the last 5 years, NovaBay Pharmaceuticals' Gross Profit tumbled by 3829.06% in 2023 and then surged by 49843.03% in 2024.
  • NovaBay Pharmaceuticals' Gross Profit (Quarter) stood at $1.7 million in 2021, then rose by 4.59% to $1.8 million in 2022, then plummeted by 38.29% to $1.1 million in 2023, then soared by 498.43% to $6.5 million in 2024, then plummeted by 99.35% to $42000.0 in 2025.
  • Its Gross Profit was $42000.0 in Q3 2025, compared to $6.5 million in Q4 2024 and $1.6 million in Q2 2024.